2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
D

2020 ASCO Update on Waldenström Macroglobulinemia: Zanubrutinib vs. Ibrutinib - Which BTKi Option is Better?

By 2020 ASCO Virtual Direct™ Highlights FEATURING David Maloney
By 2020 ASCO Virtual Direct™ Highlights FEATURING David Maloney
331 views
August 18, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Hematologic Oncology
09:23
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: Pembro vs. Brentuximab Vedotin…

Feat. D. Maloney
08:34
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Waldenström Macroglobulinemia: Zanubrutinib vs. …

Feat. D. Maloney
07:09
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on DLBCL: Venetoclax + Dose-Adjusted R-EPOCH - Did …

Feat. D. Maloney
10:30
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on FL: Is CAR-T Axi-Cel Therapy a Promising Therape…

Feat. D. Maloney